RayKnowChina Research Map
Shortlist

Blood disorders

Lymphoma in Suzhou

苏州 淋巴瘤

All diseases in Suzhou

2 hospitals in Suzhou

Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Suzhou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 48 papers led
  2. 10 papers led

Lymphoma in every city Suzhou on the disease page, with the national map

37

open trials on lymphoma with a hospital in Suzhou

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Suzhou as lead sponsor or study site. 22 of them are led by a hospital in Suzhou. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    U69-CART-Cells For R/R T-ALL
    Phase
    Phase 1
    Started
    2026-10
    Posted
    Registry
    NCT07350863

    Age 15 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  2. Recruiting
    Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07372352

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  3. Recruiting
    Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07499271

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  4. Recruiting
    An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07598578

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  5. Recruiting
    A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Posted
    Registry
    NCT06697184

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Suzhou

  6. Recruiting
    Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2025-03
    Posted
    Registry
    NCT06854445

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou

  7. Recruiting
    A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06973187

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou

  8. Recruiting
    Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07002099

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

  9. Recruiting
    Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL
    Phase
    N/A
    Started
    2025-01
    Posted
    Registry
    NCT07074470

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  10. Recruiting
    A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07124936

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou

  11. Recruiting
    Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07159620

    Age 14 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  12. Recruiting
    PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07188610

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

  13. Recruiting
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07189065

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou

  14. Recruiting
    Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07255963

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  15. Recruiting
    Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
    Phase
    Phase 4
    Started
    2025-11
    Posted
    Registry
    NCT07270835

    Age 14 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  16. Recruiting
    Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
    Phase
    Phase 1
    Started
    2025-12
    Posted
    Registry
    NCT07284927

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

  17. Recruiting
    Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07372365

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  18. Recruiting
    CMOP±R in the Treatment of Untreated Non-Hodgkin's Lymphoma
    Phase
    Phase 2
    Started
    2024-07
    Posted
    Registry
    NCT06486337

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  19. Recruiting
    Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06521255

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou

  20. Recruiting
    A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06615193

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Suzhou, Tianjin, Xuzhou, Zhengzhou

  21. Recruiting
    A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06634589

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFuzhou, Hangzhou, Suzhou, Wenzhou

  22. Recruiting
    Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06682130

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  23. Recruiting
    Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT07059741

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  24. Recruiting
    Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT07072208

    Age 70 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  25. Recruiting
    Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT07072221

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  26. Recruiting
    Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients
    Phase
    N/A
    Started
    2024-11
    Posted
    Registry
    NCT07074457

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  27. Recruiting
    Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05768529

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Shanghai, Suzhou

  28. Recruiting
    Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
    Phase
    Phase 1/Phase 2
    Started
    2022-05
    Posted
    Registry
    NCT05294731

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  29. Recruiting
    Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
    Phase
    Phase 2
    Started
    2021-12
    Posted
    Registry
    NCT05147467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesGuangzhou, Haikou, Hangzhou, Nanchang, Suzhou, Wuhan, Zhengzhou

  30. Recruiting
    Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
    Phase
    Phase 1/Phase 2
    Started
    2020-08
    Posted
    Registry
    NCT04494503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan

  31. Recruiting
    Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
    Phase
    Phase 2
    Started
    2020-01
    Posted
    Registry
    NCT05182957

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  32. Not yet recruiting
    U96-CAR-T-Cells For R/R B-ALL
    Phase
    Phase 1
    Started
    2026-07
    Posted
    Registry
    NCT07511426

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  33. Not yet recruiting
    A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07599423

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  34. Not yet recruiting
    Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
    Phase
    Not given
    Started
    2026-05
    Posted
    Registry
    NCT07609446

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  35. Not yet recruiting
    Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07774234

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow UniversitySuzhou

  36. Not yet recruiting
    A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07818499

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Suzhou

  37. Not yet recruiting
    Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL
    Phase
    N/A
    Started
    2024-02
    Posted
    Registry
    NCT06289959

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Soochow UniversitySuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Suzhou

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Suzhou, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Hospital of Soochow University太仓市第一人民医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenone0nonenonenonenonenonenonenonenonenonenone
Affiliated Suzhou Hospital of Nanjing Medical University苏州市立医院none11141928nonenonenonenonenonenone21none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone713nonenonenonenone1nonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Zhangjiagang Hospital of Soochow University苏州大学附属张家港医院nonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenone
Anhui Wanbei Coal-Electricity Group General Hospital皖北煤电集团总医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Changshu Hospital, Soochow University苏州大学附属常熟医院nonenonenonenonenonenonenonenonenonenonenone014nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Children's Hospital of Soochow University苏州大学附属儿童医院nonenonenonenonenonenonenone1111none2none161none345nonenonenonenonenone0nonenonenonenonenonenone63nonenonenonenonenonenonenone0nonenonenonenonenone1nonenone1nonenonenone3nonenonenonenonenone0none
First Affiliated Hospital of Soochow University苏州大学附属第一医院82273902 open1861 open37491 open71none22461none277 open1210 open112 open62 open4819 open16none51 opennone10none932none1753nonenonenone3none103none20none2nonenonenone21nonenonenonenonenonenonenonenonenone
Fourth Affiliated Hospital of Soochow University苏州大学附属第四医院(独墅湖医院)none3nonenonenonenonenone11 opennonenonenone1none1nonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenone1nonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Soochow University苏州大学附属第二医院54none32641 open11271 open44nonenonenone131none22nonenonenone103 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0none01none1nonenonenone0nonenonenonenonenonenonenonenonenonenone
Soochow Hopes Hematonosis Hospital苏州弘慈血液病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Suzhou Hospital苏州市中西医结合医院nonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Suzhou Hospital, Anhui Medical University宿州市立医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Suzhou Jiulong Hospital苏州九龙医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Suzhou Ninth People's Hospital苏州市第九人民医院nonenonenone16nonenonenonenonenonenonenone13nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Suzhou Tcm Hospital, Nanjing University of Tcm苏州市中医医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Suzhou Wujiang District Children's Hospital苏州市吴江区儿童医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Suzhou Xiangcheng People's Hospital苏州市相城人民医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Technology Town Hospital苏州科技城医院nonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Third Affiliated Hospital of Suzhou University苏州大学附属第三医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Suzhou.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for lymphoma.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Suzhou on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data